Last update 19 Jun 2024
CMG1A46
Last update 19 Jun 2024
Overview
Basic Info
Drug Type Trispecific T-cell engager (TriTE) |
Synonyms 1A46, BR110, CMG 1A46 + [1] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Related
3
Clinical Trials associated with CMG1A46A Phase I/II, First in Human, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of the Injection of Triple-specific T-cell Engager 1A46in Adult Subjects With R/R CD20 Positive and/or CD19 Positive B Cell Non-Hodgkin's Lymphoma (B - NHL)
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
一项评估三特异性 T 细胞介导抗体（1A46）在R/R CD20 和/或 CD19 阳性 B细胞非霍奇金淋巴瘤（B-NHL）成人受试者中安全性和有效性的I/II期、开放性、首次人体单臂研究
[Translation] A Phase I/II, open-label, first-in-human, single-arm study evaluating the safety and efficacy of a trispecific T-cell mediator antibody (1A46) in adult subjects with R/R CD20 and/or CD19-positive B-cell non-Hodgkin lymphoma (B-NHL)
100 Clinical Results associated with CMG1A46
Login to view more data
100 Translational Medicine associated with CMG1A46
Login to view more data
100 Patents (Medical) associated with CMG1A46
Login to view more data
100 Deals associated with CMG1A46
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD19 positive B-Cell Lymphoma | Phase 2 | CN | 12 Jul 2023 | |
| CD19 positive B-Cell Lymphoma | Phase 2 | CN | 12 Jul 2023 | |
| CD20 positive B-Cell Lymphoma | Phase 2 | CN | 12 Jul 2023 | |
| CD20 positive B-Cell Lymphoma | Phase 2 | CN | 12 Jul 2023 | |
| Acute Lymphoblastic Leukemia | Phase 2 | US | 30 Aug 2022 | |
| CD20 positive Hematologic Neoplasms | Phase 2 | US | 30 Aug 2022 | |
| Non-Hodgkin Lymphoma | Phase 2 | US | 30 Aug 2022 | |
| Diffuse Large B-Cell Lymphoma | Preclinical | CN | 30 Jan 2022 | |
| Follicular Lymphoma | Preclinical | CN | 30 Jan 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free